The Experts below are selected from a list of 435 Experts worldwide ranked by ideXlab platform
Koichi Otani - One of the best experts on this subject based on the ideXlab platform.
-
comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2002Co-Authors: Norio Yasuifurukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P<.01) lower than during haloperidol treatment (32 and 8–102 ng/ml), although the difference was small. The mean (±S.D.) plasma concentration of Bromperidol was significantly lower than that of haloperidol (20.8±8.0 vs. 28.0±13.1 nmol/l, P<.05). Prolactin concentrations during both treatment phases correlated well in individuals (rs=.813, P<.001), while no correlation was observed between plasma concentrations of haloperidol and Bromperidol (r=.053, ns). These findings suggest that slightly higher prolactin concentration does not necessarily lead to increased risk of hyperprolactinemia during Bromperidol treatment compared with haloperidol treatment. In addition, it is suggested that both drugs show similar pharmacodynamic response despite the difference in pharmacokinetics in the same individuals.
-
Comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in neuro-psychopharmacology & biological psychiatry, 2002Co-Authors: Norio Yasui-furukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P
-
The characteristics of side-effects of Bromperidol in schizophrenic patients.
Psychiatry and clinical neurosciences, 2002Co-Authors: Norio Yasui-furukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Osamu Tanaka, Koichi OtaniAbstract:Abstract The characteristics of the side-effects of Bromperidol was investigated in 33 acutely exacerbated schizophrenic patients. The most frequently observed side-effects were extrapyramidal symptoms. Acute dystonia developed in 10 of 33 patients, and the mean age was significantly lower (P < 0.05) in patients with dystonia (27.3 ± 6.2 years) than that in patients without dystonia (41.5 ± 12.9 years). Plasma drug concentrations were not associated with side-effects. These findings suggest that acute dystonia is affected by age factor, and that daily dosage or monitoring of drug concentration is unlikely to be a useful marker for the prediction of side-effects during Bromperidol treatment.
-
Therapeutic effects of Bromperidol on the five dimensions of schizophrenic symptoms.
Progress in neuro-psychopharmacology & biological psychiatry, 2002Co-Authors: Norio Yasui-furukori, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Akihito Suzuki, Hanako Furukori, Masayoshi Inoue, Koichi OtaniAbstract:Therapeutic profiles of Bromperidol and their relationship with plasma drug concentration and prolactin response were investigated in 30 acutely exacerbated schizophrenic patients treated with randomly allocated fixed-doses of Bromperidol (6, 12 or 18 mg/day) for 3 weeks. The mean values (±S.D.) of percentage improvement at 3 weeks in total Brief Psychiatric Rating Scale (BPRS) and five subgrouped symptoms were 59.8±29.2% for total, 64.6±37.5% for positive, 73.3±33.7% for excitement, 80.2±45.5% for cognitive, 43.1±46.5% for negative and 49.6±46.8% for anxiety–depression symptoms, respectively. Twenty (67%) of 30 patients were responders defined as having 50% or more symptom reduction significantly greater in responders than those in nonresponders after 2 weeks. Mean plasma Bromperidol concentration in patients with 50% or more reduction in positive symptoms was significantly higher than in the others (8.2±4.7 vs. 4.1±1.8 ng/ml, P
-
therapeutic effects of Bromperidol on the five dimensions of schizophrenic symptoms
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2002Co-Authors: Norio Yasuifurukori, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Akihito Suzuki, Hanako Furukori, Masayoshi Inoue, Koichi OtaniAbstract:Therapeutic profiles of Bromperidol and their relationship with plasma drug concentration and prolactin response were investigated in 30 acutely exacerbated schizophrenic patients treated with randomly allocated fixed-doses of Bromperidol (6, 12 or 18 mg/day) for 3 weeks. The mean values (±S.D.) of percentage improvement at 3 weeks in total Brief Psychiatric Rating Scale (BPRS) and five subgrouped symptoms were 59.8±29.2% for total, 64.6±37.5% for positive, 73.3±33.7% for excitement, 80.2±45.5% for cognitive, 43.1±46.5% for negative and 49.6±46.8% for anxiety–depression symptoms, respectively. Twenty (67%) of 30 patients were responders defined as having 50% or more symptom reduction significantly greater in responders than those in nonresponders after 2 weeks. Mean plasma Bromperidol concentration in patients with 50% or more reduction in positive symptoms was significantly higher than in the others (8.2±4.7 vs. 4.1±1.8 ng/ml, P<.05). Percentage improvement in total BPRS at 1 and 2 weeks were correlated well with that at 3 weeks. These findings suggest that an early improvement in positive and anxiety–depression symptoms results in favorable outcome of total response to Bromperidol treatment. Plasma drug monitoring may have a limited predictive value for improvement in positive symptoms.
Sunao Kaneko - One of the best experts on this subject based on the ideXlab platform.
-
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to Bromperidol in schizophrenic patients: A preliminary study
Progress in neuro-psychopharmacology & biological psychiatry, 2006Co-Authors: Norio Yasui-furukori, Tomonori Tateishi, Manabu Saito, Taku Nakagami, Ayako Kaneda, Sunao KanekoAbstract:The drug-transporting P-glycoprotein transports drugs against a concentration gradient across the blood-brain barrier back into the plasma and thereby reduces the bioavailability in the brain. Polymorphisms in the MDR1 gene regulating P-glycoprotein expression can be associated with differences in drug disposition in the brain. The present study was therefore designed to examine whether the major polymorphisms of MDR1 gene, C3435T and G2677T/A are related to therapeutic response to neuroleptics in the treatment of schizophrenia. Subjects consisted of 31 acutely exacerbated schizophrenic inpatients treated with Bromperidol (6-18 mg/day). Plasma drug concentrations were monitored and clinical symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The C3435T and G2677T/A genotypes were determined by a polymerase chain reaction method. Schizophrenic symptoms were allocated into 5 clusters: positive, excitement, cognitive, negative, and anxiety-depression symptoms. Patients were C/C in 12, C/T in 12 and T/T in 7 cases for C3435T genotype and G/G in 3, G/T or A in 17 and T or A/T or A in 11 cases for G2677T/A genotype. There were a tendency of difference, but not statistically different, in the percentage improvement or the improved scores of 5 sub-grouped symptoms after the 3-week treatment between C3435T genotypes and between G2677T/A genotypes. Multiple regression analyses including age, body weight, gender and drug concentration showed significant correlations between the percentage improvement and the improved scores of cognitive symptoms and C3435T genotypes. The present results suggest that the C3435T polymorphism is associated with some therapeutic response to Bromperidol in schizophrenic patients, possibly by different drug concentration in the brain.
-
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and Bromperidol.
Therapeutic drug monitoring, 2004Co-Authors: Norio Yasui-furukori, Sunao Kaneko, Yoshimasa Inoue, Hanako Furukori, Toshiyuki Someya, Manabu Saito, Tomonori TateishiAbstract:The authors have developed and verified the precision and accuracy of new automated cloned enzyme donor immunoassays (CEDIA®) for haloperidol and Bromperidol, and cross-validations have been performed with conventional semiautomated EIA kits (MARKIT®-M) and high-performance liquid chromatographic (HPLC) methods. The CEDIA® method provides a quick (about 10 minutes) assay for haloperidol or Bromperidol, requiring no serum/plasma pretreatment or predilution. The CEDIA® haloperidol/Bromperidol assay showed little or no cross reactivity with either their metabolites or many drugs commonly coprescribed. MARKIT®-M revealed considerable cross reactivity values proportional to the spiked amounts of reduced metabolites. Precision, accuracy, recovery, and linearity testing for the CEDIA® assay were all sufficient for clinical use. Significant linear correlations were found between CEDIA® and HPLC in measuring haloperidol (CEDIA® = 1.06 × HPLC + 0.869; n = 44, rs = 0.913, P < 0.001) and Bromperidol (CEDIA® = 1.06 × HPLC + 0.606; n = 56, rs = 0.914, P < 0.001) concentrations. This study has, therefore, demonstrated that the CEDIA® assay has a quick run time with high precision and accuracy, and this method is a useful tool for the TDM of haloperidol or Bromperidol.
-
Poor reliability of therapeutic drug monitoring data for haloperidol and Bromperidol using enzyme immunoassay.
Therapeutic drug monitoring, 2003Co-Authors: Norio Yasui-furukori, Sunao Kaneko, Yoshimasa Inoue, Hanako Furukori, Manabu Saito, Tomonori TateishiAbstract:Therapeutic drug monitoring (TDM) services for plasma concentrations of haloperidol and Bromperidol using enzyme immunoassay (EIA) methods are available in Japan, whereas high-performance liquid chromatographic (HPLC) methods are preferred in other countries. To compare these methods, we took 54 plasma samples for haloperidol and 91 plasma samples for Bromperidol from schizophrenic patients receiving haloperidol or Bromperidol, and the samples were measured using both commercial EIA and HPLC methods. Significant linear correlations were found between the two methods in determining haloperidol (EIA = 1.351 × HPLC + 1.39; r = 0.934, P < 0.001) and Bromperidol (EIA = 1.420 x HPLC + 0.712; r = 0.956, P < 0.001) concentrations, but plasma concentrations using the EIA kits were approximately 92% (95% CI; 53-131%) and 62% (54-70%) higher than those using HPLC for haloperidol and Bromperidol, respectively. Mean (and range) plasma concentrations of reduced metabolites were 54% (30-92%) and 55% (29-111%) of those of haloperidol and Bromperidol, respectively. The present study suggests that reduced metabolites are included to a considerable degree in TDM data using the EIA kits. Therefore, some limitation of TDM data of haloperidol and Bromperidol using the EIA kits, ie, high precision but poor accuracy, should be kept in mind.
-
comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2002Co-Authors: Norio Yasuifurukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P<.01) lower than during haloperidol treatment (32 and 8–102 ng/ml), although the difference was small. The mean (±S.D.) plasma concentration of Bromperidol was significantly lower than that of haloperidol (20.8±8.0 vs. 28.0±13.1 nmol/l, P<.05). Prolactin concentrations during both treatment phases correlated well in individuals (rs=.813, P<.001), while no correlation was observed between plasma concentrations of haloperidol and Bromperidol (r=.053, ns). These findings suggest that slightly higher prolactin concentration does not necessarily lead to increased risk of hyperprolactinemia during Bromperidol treatment compared with haloperidol treatment. In addition, it is suggested that both drugs show similar pharmacodynamic response despite the difference in pharmacokinetics in the same individuals.
-
Comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in neuro-psychopharmacology & biological psychiatry, 2002Co-Authors: Norio Yasui-furukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P
Yoshimasa Inoue - One of the best experts on this subject based on the ideXlab platform.
-
simultaneous determination of haloperidol and Bromperidol and their reduced metabolites by liquid liquid extraction and automated column switching high performance liquid chromatography
Journal of Chromatography B, 2004Co-Authors: Norio Yasuifurukori, Yoshimasa Inoue, Misturu Chiba, Tomonori TateishiAbstract:Abstract This study describes a new simultaneous determination of haloperidol and Bromperidol and their reduced metabolites by modification of automated column-switching high-performance liquid chromatography. The test compounds were extracted from 1 ml of plasma using chloroform–hexane (30:70 (v/v)), and the extract was injected into a hydrophilic metaacrylate polymer column for clean-up and a C 18 analytical column for separation. The mobile phases consisted of phosphate buffer (0.02 M, pH 4.6), perchloric acid (60%) and acetonitrile (54:1:45 (v/v)) and was delivered at a flow-rate of 0.6 ml/min. The peak was detected using a UV detector set at 215 nm. The method was validated for the concentration range 1–100 ng/ml, and good linearity ( r >0.999) was confirmed. Intra-day coefficient variations (CVs) for haloperidol, reduced haloperidol, Bromperidol and reduced Bromperidol were less than 2.5, 3.1, 2.4 and 2.5%, respectively. Inter-day CVs for corresponding compounds were 3.9, 5.1, 2.6 and 4.4%, respectively. Relative errors ranged from −5 to 10% and mean recoveries were 96–100%. The limit of quantification was 1.0 ng/m for each compound. This method shows good specificity with respect to commonly prescribed psychotropic drugs, and it could be successfully applied for pharmacokinetic studies and therapeutic drug monitoring, particularly in patients receiving both haloperidol and Bromperidol.
-
Simultaneous determination of haloperidol and Bromperidol and their reduced metabolites by liquid–liquid extraction and automated column-switching high-performance liquid chromatography
Journal of chromatography. B Analytical technologies in the biomedical and life sciences, 2004Co-Authors: Norio Yasui-furukori, Yoshimasa Inoue, Misturu Chiba, Tomonori TateishiAbstract:Abstract This study describes a new simultaneous determination of haloperidol and Bromperidol and their reduced metabolites by modification of automated column-switching high-performance liquid chromatography. The test compounds were extracted from 1 ml of plasma using chloroform–hexane (30:70 (v/v)), and the extract was injected into a hydrophilic metaacrylate polymer column for clean-up and a C 18 analytical column for separation. The mobile phases consisted of phosphate buffer (0.02 M, pH 4.6), perchloric acid (60%) and acetonitrile (54:1:45 (v/v)) and was delivered at a flow-rate of 0.6 ml/min. The peak was detected using a UV detector set at 215 nm. The method was validated for the concentration range 1–100 ng/ml, and good linearity ( r >0.999) was confirmed. Intra-day coefficient variations (CVs) for haloperidol, reduced haloperidol, Bromperidol and reduced Bromperidol were less than 2.5, 3.1, 2.4 and 2.5%, respectively. Inter-day CVs for corresponding compounds were 3.9, 5.1, 2.6 and 4.4%, respectively. Relative errors ranged from −5 to 10% and mean recoveries were 96–100%. The limit of quantification was 1.0 ng/m for each compound. This method shows good specificity with respect to commonly prescribed psychotropic drugs, and it could be successfully applied for pharmacokinetic studies and therapeutic drug monitoring, particularly in patients receiving both haloperidol and Bromperidol.
-
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and Bromperidol.
Therapeutic drug monitoring, 2004Co-Authors: Norio Yasui-furukori, Sunao Kaneko, Yoshimasa Inoue, Hanako Furukori, Toshiyuki Someya, Manabu Saito, Tomonori TateishiAbstract:The authors have developed and verified the precision and accuracy of new automated cloned enzyme donor immunoassays (CEDIA®) for haloperidol and Bromperidol, and cross-validations have been performed with conventional semiautomated EIA kits (MARKIT®-M) and high-performance liquid chromatographic (HPLC) methods. The CEDIA® method provides a quick (about 10 minutes) assay for haloperidol or Bromperidol, requiring no serum/plasma pretreatment or predilution. The CEDIA® haloperidol/Bromperidol assay showed little or no cross reactivity with either their metabolites or many drugs commonly coprescribed. MARKIT®-M revealed considerable cross reactivity values proportional to the spiked amounts of reduced metabolites. Precision, accuracy, recovery, and linearity testing for the CEDIA® assay were all sufficient for clinical use. Significant linear correlations were found between CEDIA® and HPLC in measuring haloperidol (CEDIA® = 1.06 × HPLC + 0.869; n = 44, rs = 0.913, P < 0.001) and Bromperidol (CEDIA® = 1.06 × HPLC + 0.606; n = 56, rs = 0.914, P < 0.001) concentrations. This study has, therefore, demonstrated that the CEDIA® assay has a quick run time with high precision and accuracy, and this method is a useful tool for the TDM of haloperidol or Bromperidol.
-
Poor reliability of therapeutic drug monitoring data for haloperidol and Bromperidol using enzyme immunoassay.
Therapeutic drug monitoring, 2003Co-Authors: Norio Yasui-furukori, Sunao Kaneko, Yoshimasa Inoue, Hanako Furukori, Manabu Saito, Tomonori TateishiAbstract:Therapeutic drug monitoring (TDM) services for plasma concentrations of haloperidol and Bromperidol using enzyme immunoassay (EIA) methods are available in Japan, whereas high-performance liquid chromatographic (HPLC) methods are preferred in other countries. To compare these methods, we took 54 plasma samples for haloperidol and 91 plasma samples for Bromperidol from schizophrenic patients receiving haloperidol or Bromperidol, and the samples were measured using both commercial EIA and HPLC methods. Significant linear correlations were found between the two methods in determining haloperidol (EIA = 1.351 × HPLC + 1.39; r = 0.934, P < 0.001) and Bromperidol (EIA = 1.420 x HPLC + 0.712; r = 0.956, P < 0.001) concentrations, but plasma concentrations using the EIA kits were approximately 92% (95% CI; 53-131%) and 62% (54-70%) higher than those using HPLC for haloperidol and Bromperidol, respectively. Mean (and range) plasma concentrations of reduced metabolites were 54% (30-92%) and 55% (29-111%) of those of haloperidol and Bromperidol, respectively. The present study suggests that reduced metabolites are included to a considerable degree in TDM data using the EIA kits. Therefore, some limitation of TDM data of haloperidol and Bromperidol using the EIA kits, ie, high precision but poor accuracy, should be kept in mind.
-
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to Bromperidol.
American journal of medical genetics, 2001Co-Authors: Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi Otani, Norio Yasui-furukori, Shingo Ono, Yoshimasa InoueAbstract:The dopamine D2 receptor (DRD2) gene has a Taq1 A restriction fragment length polymorphism yielding two alleles, A1 and A2. We have previously shown that female patients with the A1 allele show greater prolactin response to nemonapride, a selective antagonist for D2-like dopamine receptors, in schizophrenic patients. In the present study, the relationship between this polymorphism and prolactin response to Bromperidol was investigated in 32 untreated schizophrenic inpatients (16 males, 16 females). The daily dose of Bromperidol was fixed at 6 (n= 10), 12 (n= 13), or 18 mg (n=9) during a 2-week treatment period. Taq1 A genotypes were determined by PCR method. Plasma prolactin concentration was measured by radioimmunoassay. Plasma concentration of Bromperidol was measured by HPLC method. The subjects were divided into four subgroups by gender and the genotypes, i.e., 10 males and 11 females with the A1 allele, 6 males and 5 females with no A1 allele. The females with the A1 allele had the highest Δ prolactin (the change from the pretreatment concentration)/Bromperidol concentration ratio among the other groups (P < 0.05). The present study thus suggests that female patients with the A1 allele show greater prolactin response to Bromperidol, who may have a high risk for adverse effects associated with neuroleptic-induced hyperprolactinemia.
Akihito Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2002Co-Authors: Norio Yasuifurukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P<.01) lower than during haloperidol treatment (32 and 8–102 ng/ml), although the difference was small. The mean (±S.D.) plasma concentration of Bromperidol was significantly lower than that of haloperidol (20.8±8.0 vs. 28.0±13.1 nmol/l, P<.05). Prolactin concentrations during both treatment phases correlated well in individuals (rs=.813, P<.001), while no correlation was observed between plasma concentrations of haloperidol and Bromperidol (r=.053, ns). These findings suggest that slightly higher prolactin concentration does not necessarily lead to increased risk of hyperprolactinemia during Bromperidol treatment compared with haloperidol treatment. In addition, it is suggested that both drugs show similar pharmacodynamic response despite the difference in pharmacokinetics in the same individuals.
-
Comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in neuro-psychopharmacology & biological psychiatry, 2002Co-Authors: Norio Yasui-furukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P
-
Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs
International Congress Series, 2002Co-Authors: Tsuyoshi Kondo, Kazuo Mihara, Sunao Kaneko, Akihito Suzuki, Norio Yasui-furukori, Shingo Ono, Koichi OtaniAbstract:Abstract Cytochrome P 450 (CYP) 2D6 activity is genetically determined, yielding extensive metabolizers (EMs) and poor metabolizers (PMs). Because of the involvement of this enzyme in the metabolism of many antipsychotic drugs, clinical implication of CYP2D6 genotyping has been expected for tailor-made antipsychotic drug therapy. Genotyping analysis showed that the mean steady-state plasma concentration ( C ss ) of haloperidol in subjects with no mutated alleles was higher than those in subjects with one and two mutated alleles. However, large overlaps in the C ss were observed among these genotype groups. The C ss of Bromperidol was not affected by CYP2D6 genotypes. These results suggest that CYP2D6 genotype does not predict the C ss of haloperidol or Bromperidol. It was also shown that the active moiety of risperidone (plasma concentrations of risperidone plus 9-hydroxyrisperidone) did not differ between EMs and PMs of CYP2D6, although 9-hydroxylation of risperidone is highly dependent on CYP2D6 activity. Nevertheless, CYP2D6 genotyping may be useful if drugs fulfill such conditions as: (1) specific substrates for CYP2D6, (2) established concentration–effect relationship, and (3) no active metabolites. High frequency of *10 allele in Orientals will also justify importance of CYP2D6 genotyping in subjects treated with such kind of antipsychotic drugs in the future.
-
Therapeutic effects of Bromperidol on the five dimensions of schizophrenic symptoms.
Progress in neuro-psychopharmacology & biological psychiatry, 2002Co-Authors: Norio Yasui-furukori, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Akihito Suzuki, Hanako Furukori, Masayoshi Inoue, Koichi OtaniAbstract:Therapeutic profiles of Bromperidol and their relationship with plasma drug concentration and prolactin response were investigated in 30 acutely exacerbated schizophrenic patients treated with randomly allocated fixed-doses of Bromperidol (6, 12 or 18 mg/day) for 3 weeks. The mean values (±S.D.) of percentage improvement at 3 weeks in total Brief Psychiatric Rating Scale (BPRS) and five subgrouped symptoms were 59.8±29.2% for total, 64.6±37.5% for positive, 73.3±33.7% for excitement, 80.2±45.5% for cognitive, 43.1±46.5% for negative and 49.6±46.8% for anxiety–depression symptoms, respectively. Twenty (67%) of 30 patients were responders defined as having 50% or more symptom reduction significantly greater in responders than those in nonresponders after 2 weeks. Mean plasma Bromperidol concentration in patients with 50% or more reduction in positive symptoms was significantly higher than in the others (8.2±4.7 vs. 4.1±1.8 ng/ml, P
-
therapeutic effects of Bromperidol on the five dimensions of schizophrenic symptoms
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2002Co-Authors: Norio Yasuifurukori, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Akihito Suzuki, Hanako Furukori, Masayoshi Inoue, Koichi OtaniAbstract:Therapeutic profiles of Bromperidol and their relationship with plasma drug concentration and prolactin response were investigated in 30 acutely exacerbated schizophrenic patients treated with randomly allocated fixed-doses of Bromperidol (6, 12 or 18 mg/day) for 3 weeks. The mean values (±S.D.) of percentage improvement at 3 weeks in total Brief Psychiatric Rating Scale (BPRS) and five subgrouped symptoms were 59.8±29.2% for total, 64.6±37.5% for positive, 73.3±33.7% for excitement, 80.2±45.5% for cognitive, 43.1±46.5% for negative and 49.6±46.8% for anxiety–depression symptoms, respectively. Twenty (67%) of 30 patients were responders defined as having 50% or more symptom reduction significantly greater in responders than those in nonresponders after 2 weeks. Mean plasma Bromperidol concentration in patients with 50% or more reduction in positive symptoms was significantly higher than in the others (8.2±4.7 vs. 4.1±1.8 ng/ml, P<.05). Percentage improvement in total BPRS at 1 and 2 weeks were correlated well with that at 3 weeks. These findings suggest that an early improvement in positive and anxiety–depression symptoms results in favorable outcome of total response to Bromperidol treatment. Plasma drug monitoring may have a limited predictive value for improvement in positive symptoms.
Tsuyoshi Kondo - One of the best experts on this subject based on the ideXlab platform.
-
Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia.
Psychiatry and clinical neurosciences, 2005Co-Authors: Jijun Wang, Tsuyoshi Kondo, Yoshio Hirayasu, Hiroto Hokama, Shin Tanaka, Mingdao Zhang, Zeping XiaoAbstract:P300 amplitude reduction in schizophrenia is, according to previous studies, partially recovered by treatment with neuroleptics. However, whether this medication-induced P300 recovery is associated with duration of untreated psychosis (DUP) remains unreported; the present study is a preliminary examination of this question. Auditory P300 was recorded from 18 drug-naive and first-episode schizophrenia patients, among whom 10 were identified as short DUP, and eight as long DUP. Follow-up event-related potential tests were carried out after treatment with haloperidol or Bromperidol for approximately 2 months. Recovery of P300 amplitude was replicated after neuroleptic medication was administered. A significant interaction was found between DUP and the medication effect in P300 amplitude over the left temporo-parietal area; a significant P300 recovery was seen in short DUP but not in long DUP. These results suggest that first-episode schizophrenia patients with long DUP might have severe impairments in the left temporal structures, supporting DUP as a key variable in future neurobiological studies of first-episode schizophrenia.
-
comparison of prolactin concentrations between haloperidol and Bromperidol treatments in schizophrenic patients
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2002Co-Authors: Norio Yasuifurukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Akihito Suzuki, Koichi OtaniAbstract:The antipsychotic drug, Bromperidol, is a close structural analogue of haloperidol. These two drugs also have similarities in metabolic pathways and pharmacological properties. In the present study, the prolactin concentrations in plasma during Bromperidol versus haloperidol treatments were compared in the same individuals. The subjects were 22 schizophrenic inpatients, who first received Bromperidol 12 mg/day for at least 2 weeks followed by haloperidol 12 mg/day. The prolactin concentration in plasma during Bromperidol treatment (median and range; 24 and 7–93 ng/ml, respectively) was significantly (P<.01) lower than during haloperidol treatment (32 and 8–102 ng/ml), although the difference was small. The mean (±S.D.) plasma concentration of Bromperidol was significantly lower than that of haloperidol (20.8±8.0 vs. 28.0±13.1 nmol/l, P<.05). Prolactin concentrations during both treatment phases correlated well in individuals (rs=.813, P<.001), while no correlation was observed between plasma concentrations of haloperidol and Bromperidol (r=.053, ns). These findings suggest that slightly higher prolactin concentration does not necessarily lead to increased risk of hyperprolactinemia during Bromperidol treatment compared with haloperidol treatment. In addition, it is suggested that both drugs show similar pharmacodynamic response despite the difference in pharmacokinetics in the same individuals.
-
Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs
International Congress Series, 2002Co-Authors: Tsuyoshi Kondo, Kazuo Mihara, Sunao Kaneko, Akihito Suzuki, Norio Yasui-furukori, Shingo Ono, Koichi OtaniAbstract:Abstract Cytochrome P 450 (CYP) 2D6 activity is genetically determined, yielding extensive metabolizers (EMs) and poor metabolizers (PMs). Because of the involvement of this enzyme in the metabolism of many antipsychotic drugs, clinical implication of CYP2D6 genotyping has been expected for tailor-made antipsychotic drug therapy. Genotyping analysis showed that the mean steady-state plasma concentration ( C ss ) of haloperidol in subjects with no mutated alleles was higher than those in subjects with one and two mutated alleles. However, large overlaps in the C ss were observed among these genotype groups. The C ss of Bromperidol was not affected by CYP2D6 genotypes. These results suggest that CYP2D6 genotype does not predict the C ss of haloperidol or Bromperidol. It was also shown that the active moiety of risperidone (plasma concentrations of risperidone plus 9-hydroxyrisperidone) did not differ between EMs and PMs of CYP2D6, although 9-hydroxylation of risperidone is highly dependent on CYP2D6 activity. Nevertheless, CYP2D6 genotyping may be useful if drugs fulfill such conditions as: (1) specific substrates for CYP2D6, (2) established concentration–effect relationship, and (3) no active metabolites. High frequency of *10 allele in Orientals will also justify importance of CYP2D6 genotyping in subjects treated with such kind of antipsychotic drugs in the future.
-
The characteristics of side-effects of Bromperidol in schizophrenic patients.
Psychiatry and clinical neurosciences, 2002Co-Authors: Norio Yasui-furukori, Kazuo Mihara, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Osamu Tanaka, Koichi OtaniAbstract:Abstract The characteristics of the side-effects of Bromperidol was investigated in 33 acutely exacerbated schizophrenic patients. The most frequently observed side-effects were extrapyramidal symptoms. Acute dystonia developed in 10 of 33 patients, and the mean age was significantly lower (P < 0.05) in patients with dystonia (27.3 ± 6.2 years) than that in patients without dystonia (41.5 ± 12.9 years). Plasma drug concentrations were not associated with side-effects. These findings suggest that acute dystonia is affected by age factor, and that daily dosage or monitoring of drug concentration is unlikely to be a useful marker for the prediction of side-effects during Bromperidol treatment.
-
Therapeutic effects of Bromperidol on the five dimensions of schizophrenic symptoms.
Progress in neuro-psychopharmacology & biological psychiatry, 2002Co-Authors: Norio Yasui-furukori, Tsuyoshi Kondo, Sunao Kaneko, Masayuki Ishida, Akihito Suzuki, Hanako Furukori, Masayoshi Inoue, Koichi OtaniAbstract:Therapeutic profiles of Bromperidol and their relationship with plasma drug concentration and prolactin response were investigated in 30 acutely exacerbated schizophrenic patients treated with randomly allocated fixed-doses of Bromperidol (6, 12 or 18 mg/day) for 3 weeks. The mean values (±S.D.) of percentage improvement at 3 weeks in total Brief Psychiatric Rating Scale (BPRS) and five subgrouped symptoms were 59.8±29.2% for total, 64.6±37.5% for positive, 73.3±33.7% for excitement, 80.2±45.5% for cognitive, 43.1±46.5% for negative and 49.6±46.8% for anxiety–depression symptoms, respectively. Twenty (67%) of 30 patients were responders defined as having 50% or more symptom reduction significantly greater in responders than those in nonresponders after 2 weeks. Mean plasma Bromperidol concentration in patients with 50% or more reduction in positive symptoms was significantly higher than in the others (8.2±4.7 vs. 4.1±1.8 ng/ml, P
